Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 3
2019 7
2020 6
2021 7
2022 4
2023 2
2024 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.
Laohapiboolrattana W, Jansem P, Anukoolwittaya P, Roongpiboonsopit D, Hiransuthikul A, Pongpitakmetha T, Thanprasertsuk S, Rattanawong W. Laohapiboolrattana W, et al. J Headache Pain. 2024 Nov 8;25(1):194. doi: 10.1186/s10194-024-01904-1. J Headache Pain. 2024. PMID: 39516789 Free PMC article.
BACKGROUND: Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient responders with minimal existing comparative data. ...CONCLUSION: Lasmiditan, rimegepant, and ubrogepant are effective for acute treatm …
BACKGROUND: Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient re …
Lasmiditan for acute treatment of migraine.
Parikh S. Parikh S. Drugs Today (Barc). 2021 Feb;57(2):89-100. doi: 10.1358/dot.2021.57.2.3238326. Drugs Today (Barc). 2021. PMID: 33656015 Review.
Lasmiditan, a selective 5-HT1F receptor agonist, is a harbinger for the novel ditan class of medications for acute migraine treatment. ...Notably, lasmiditan does not result in vasoconstriction, making lasmiditan a migraine-specific acute treatm …
Lasmiditan, a selective 5-HT1F receptor agonist, is a harbinger for the novel ditan class of medications for acute migraine tr …
Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review.
Ferrari A, Rustichelli C. Ferrari A, et al. Clin Ther. 2021 Apr;43(4):654-670. doi: 10.1016/j.clinthera.2021.01.020. Epub 2021 Feb 16. Clin Ther. 2021. PMID: 33608115 Review.
PURPOSE: This narrative review provides an update on the research that led to the development of ditans and lasmiditan for the acute treatment of migraine in adults and discusses the potential advantages and disadvantages of lasmiditan in clinical use. …
PURPOSE: This narrative review provides an update on the research that led to the development of ditans and lasmiditan for the …
Headache: Treatment update.
Ogunlaja OI, Goadsby PJ. Ogunlaja OI, et al. eNeurologicalSci. 2022 Aug 17;29:100420. doi: 10.1016/j.ensci.2022.100420. eCollection 2022 Dec. eNeurologicalSci. 2022. PMID: 36636337 Free PMC article. Review.
Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the a …
Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high bu …
Ditans: a new prospective for the therapy of migraine attack?
Viticchi G, Falsetti L, Silvestrini M, Bartolini M. Viticchi G, et al. Neurol Sci. 2022 Sep;43(9):5709-5716. doi: 10.1007/s10072-022-06260-z. Epub 2022 Jul 11. Neurol Sci. 2022. PMID: 35816257 Review.
This review aimed to analyze studies related to the category of "ditans," with a focus on lasmiditan, which is available for human use. MATERIALS AND METHODS: We consulted PubMed/MEDLINE, Web of Science, and www. CLINICALTRIALS: gov to find both original and review …
This review aimed to analyze studies related to the category of "ditans," with a focus on lasmiditan, which is available for h …
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.
Puledda F, Younis S, Huessler EM, Haghdoost F, Lisicki M, Goadsby PJ, Tassorelli C. Puledda F, et al. Cephalalgia. 2023 Mar;43(3):3331024231151419. doi: 10.1177/03331024231151419. Cephalalgia. 2023. PMID: 36786357 Free article.
Phase 3 randomized controlled trials examining all formulations of lasmiditan, rimegepant and ubrogepant for the acute treatment of adults with migraine, were included. ...The odds of treatment-emergent adverse events were greatest with all doses of lasmiditan …
Phase 3 randomized controlled trials examining all formulations of lasmiditan, rimegepant and ubrogepant for the acute treatment of a …
Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment.
Belvís R, Irimia P, González N, García-Ull J, Pozo-Rosich P, López-Bravo A, Morollón N, Quintas S, Plana A, Baz PG, Tentor A, Gallego Artiles N, León FJ, Pérez Martín M, Rivera I, Ramírez R, Colomina I, Lainez JM, Pascual J. Belvís R, et al. Med Clin (Barc). 2024 Aug 30;163(4):208.e1-208.e10. doi: 10.1016/j.medcli.2024.02.006. Epub 2024 Apr 19. Med Clin (Barc). 2024. PMID: 38643025 English, Spanish.
Migraine is a disease with a high prevalence and incidence, in addition to being highly disabling, causing a great impact on the patient's quality of life at a personal, family and work level, but also social, given its high expense due to its direct (care) and indirect (p …
Migraine is a disease with a high prevalence and incidence, in addition to being highly disabling, causing a great impact on the pati …
Lasmiditan: an additional therapeutic option for the acute treatment of migraine.
Martinelli D, Bitetto V, Tassorelli C. Martinelli D, et al. Expert Rev Neurother. 2021 May;21(5):491-502. doi: 10.1080/14737175.2021.1912599. Epub 2021 Apr 19. Expert Rev Neurother. 2021. PMID: 33866907 Review.
Our evaluation considered original papers and review articles published from 2010 to 2020.Expert opinion: Available data point to the efficacy of lasmiditan in reducing migraine pain and the most bothersome symptoms within 2 hours from oral administration. Moreover, …
Our evaluation considered original papers and review articles published from 2010 to 2020.Expert opinion: Available data point to the effica …
Profiling lasmiditan as a treatment option for migraine.
Curto M, Cipolla F, Cisale GY, Capi M, Spuntarelli V, Guglielmetti M, Martelletti P, Lionetto L. Curto M, et al. Expert Opin Pharmacother. 2020 Feb;21(2):147-153. doi: 10.1080/14656566.2019.1694004. Epub 2019 Nov 25. Expert Opin Pharmacother. 2020. PMID: 31766908 Review.
A novel migraine drug class, called 'neurally acting anti-migraine agents', has been developed for the management of acute migraine attacks. ...Original research and review articles, relative to the period 2010-2019, were included in the reviewed literature.E …
A novel migraine drug class, called 'neurally acting anti-migraine agents', has been developed for the management of acute …
The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'.
Xavier AS, Lakshmanan M, Gunaseelan V. Xavier AS, et al. Curr Clin Pharmacol. 2017;12(1):36-40. doi: 10.2174/1574884712666170419155048. Curr Clin Pharmacol. 2017. PMID: 28425871 Review.
Migraine is a recurrent, disabling, complex and highly prevalent neurological disorder. ...The role of mediators such as Calcitonin Gene-Related Peptide (CGRP), nitric oxide and excitatory neurotransmitter glutamate, has been realized and ignited the development of drugs t …
Migraine is a recurrent, disabling, complex and highly prevalent neurological disorder. ...The role of mediators such as Calcitonin G …
33 results